PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline

Overview of attention for article published in Journal of Clinical Oncology, August 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 40 news outlets
twitter: 97 X users
facebook: 2 Facebook pages

f1000: 1 research highlight platform
guideline: 3 clinical guideline sources

Readers on

mendeley: 97 Mendeley

So far, Altmetric has seen 115 X posts from 97 X users, with an upper bound of 481,851 followers.

RT @TaylorJolyn: Great summary of recommendations for parps in #ovariancancer ! https://t.co/59XULoCSXx

RT @nicoleflemingmd: Great reference @LHavrilesky for #Parp inhibitors in #ovariancancer #gyncsm

RT @nicoleflemingmd: Great reference @LHavrilesky for #Parp inhibitors in #ovariancancer #gyncsm https://t.co/JMkUOubVxN

RT @womenofteal: T6 The PATIENT AND CLINICIAN COMMUNICATION section of the @ASCO guideline highlights the psychosocial support for women ta…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 111 additional X posts.